Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Assessing PFS and alternative endpoints for advanced cancer clinical trials

Jurjen Versluis • 22 Apr 2024
EBMT 2024
General

Jurjen Versluis, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses progression-free survival (PFS) as an endpoint in advanced cancer clinical trials and other endpoints that may be suitable alternatives. Dr Verluis emphasizes the importance of long-term follow-up to assess overall survival (OS) benefits, as well as the validation of alternative endpoints such as measurable residual disease (MRD). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jurjen Versluis

The curative potential of alloSCT in the treatment of HR-MDS
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
Integrating genomics and MRD in transplant decision-making for patients with AML
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals